Stephen H. Caldwell, MD
Graduate School: Bowman Gray School of Medicine (MD); Salem VA and Roanoke Hospital (residency); UVA (Gastrology fellowship); Univ of Miami (Hepatology fellowship)
Primary Appointment: Professor, Medicine, Gastroenterology and Hepatology
Steatohepatitis, cirrhosis, variceal bleeding, hepatocellular cancer, coagulopathy in liver disease, and viral hepatitis
Email Address: firstname.lastname@example.org
Dr. Caldwell's research work focuses on several areas of Hepatology including fatty liver disease, coagulopathy and hemostasis in liver disease, gastric variceal bleeding, viral hepatitis, hepatocellular cancer, alcoholic liver disease, ascites, techniques in liver biopsy.
Dr. Caldwell is best known for work during the early years of the study of NASH (non-alcoholic steatohepatitis) where he and colleagues contributed many seminal concepts, Coagulation Disorders in Liver disease (see www.coagulationinliverdisease.org) which is ongoing and promises to change key management aspects in chronic liver disease and work with cyanoacrylates in the treatment of variceal bleeding which has advanced management of this challenging problem through work with the UVA multidisciplinary team.
Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, Pramoonjago P, Simmons W, Scruggs H, Rosenbaum N, Wilkinson T, Toms P, Argo CK, Al-Osaimi AM, Redick JA. Hepatocellular ballooning in NASH. J Hepatol. 2010 Oct;53(4):719-23. doi: 10.1016/j.jhep.2010.04.031. Epub 2010 Jun 25
Caldwell SH, de Freitas LA, Park SH, Moreno ML, Redick JA, Davis CA, Sisson BJ, Patrie JT, Cotrim H, Argo CK, Al-Osaimi A. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis. Hepatology. 2009 Jun;49(6):1888-95. doi: 10.1002/hep.22851.
de Lima VM, Oliveira CP, Alves VA, Chammas MC, Oliveira EP, Stefano JT, de Mello ES, Cerri GG, Carrilho FJ, Caldwell SH. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J Hepatol. 2008 Dec;49(6):1055-61. doi: 10.1016/j.jhep.2008.07.024. Epub 2008 Sep 24.
Caldwell SH, Patrie JT, Brunt EM, Redick JA, Davis CA, Park SH, Neuschwander-Tetri BA. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. Hepatology. 2007 Oct;46(4):1101-7.
Caldwell SH, Argo CK. Divergent effects of peroxisome
proliferator-activated receptor-gamma ligands in human and mouse
Northup PG, Caldwell SH. Coagulation in Liver Disease: A Guide for theClinician. Clin Gastroenterol Hepatol. 2013 Mar 16. doi:pii:S1542-3565(13)00317-0. 10.1016/j.cgh.2013.02.026. [Epub ahead of print]
Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol. 2012Sep-Oct;11(5):686-90.
Saad WE, Al-Osaimi AM, Caldwell SH. Pre- and post-balloon-occluded retrograde transvenous obliteration clinical evaluation, management, and imaging:indications, management protocols, and follow-up. Tech Vasc Interv Radiol. 2012Sep;15(3):165-202. doi: 10.1053/j.tvir.2012.07.003. Review.
Northup PG, Argo CK, Shah N, Caldwell SH. Hypercoagulation and thrombophiliain nonalcoholic fatty liver disease: mechanisms, human evidence, therapeuticimplications, and preventive implications. Semin Liver Dis. 2012 Feb;32(1):39-48.doi: 10.1055/s-0032-1306425. Epub 2012 Mar 13. Review.
Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholicsteatohepatitis. Clin Liver Dis. 2009 Nov;13(4):511-31. doi:10.1016/j.cld.2009.07.005.